Partnership to Aid Access to Man-made FVIII for Patients in China

Partnership to Aid Access to Man-made FVIII for Patients in China

295955

Partnership to Aid Access to Man-made FVIII for Patients in China

GenScript ProBio and Neoletix Biotechnology have entered into an agreement for clinical and commercial production of a lab-made version of coagulation factor VIII, a product that the companies hope will make the preventive treatment for hemophilia A more accessible to patients in China. Coagulation factor VIII, or FVIII, is a protein that is needed for blood to clot properly. In people with hemophilia A, this protein is either missing or unable to function properly, resulting…

You must be logged in to read/download the full post.